Inflammation in Covid-19: Exploration of Critical Aspects of Pathogenesis (ICECAP)

Grant number: COV/EDI/20/10

Grant search

Key facts

  • Disease

    COVID-19
  • Known Financial Commitments (USD)

    $198,400
  • Funder

    CSO Scotland
  • Principal Investigator

    David Dorward
  • Research Location

    United Kingdom
  • Lead Research Institution

    University of Edinburgh
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The COVID-19 pandemic is causing widespread illness and death, with lung damage characterising severe disease. How the virus causes lung injury is not understood and no treatments exist. It is therefore urgent and vital that the effects of severe COVID-19 are described to rapidly inform clinical management and identify new treatments. Hospital post-mortems of those dying from COVID-19 will allow examination in a level of detail that is not possible during life. This approach will reveal crucial information on the presence of the coronavirus in multiple organs in the body and also understand how the immune system responds. This will rapidly answer key clinical questions and develop a resource of stored tissue that will support international-level COVID-19 research.

Publicationslinked via Europe PMC

Last Updated:2 hours ago

View all publications at Europe PMC

Tissue Proteomic Analysis Identifies Mechanisms and Stages of Immunopathology in Fatal COVID-19.

Intestinal Protein Characterisation of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in Inflammatory Bowel Disease (IBD) and Fatal COVID-19 Infection.

Tissue-Specific Immunopathology in Fatal COVID-19.

Histological Evidence of Pulmonary Microthrombosis and Vasculitis in Life-Threatening Respiratory Virus Diseases.